ABSTRACT
The potential of using antibodies directed to tumor-associated antigens has been the basis of a great deal of work for the selective delivery of radiation to tumors, giving rise to the field of radioimmunotherapy (RIT). Despite its theoretical appeal, this approach has been only modestly successful to date for the treatment of carcinomas including lung, colon, breast, prostate, and pancreatic cancers. Conventional RIT, a modality involving direct covalent coupling of a radionuclide or radiometal chelate to immunoglobulins, has unfortunately exhibited suboptimal therapeutic efficacy due to inadequate delivery of radiation to tumors.
